Loading…
NeuroSense Therapeutics Ltd. is projected to rise to $1.01 by 2027, a +13% move from its current price of $0.8953. NRSN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.8644 | $0.8962 | $0.9292 | +0.11% |
| May 30 | $0.8525 | $0.8972 | $0.9443 | +0.21% |
| May 31 | $0.8436 | $0.8981 | $0.9562 | +0.32% |
| Jun 1 | $0.8364 | $0.8991 | $0.9665 | +0.42% |
| Jun 2 | $0.8301 | $0.90 | $0.9758 | +0.53% |
| Jun 3 | $0.8246 | $0.901 | $0.9844 | +0.64% |
| Jun 4 | $0.8197 | $0.902 | $0.9925 | +0.74% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.8197 | $0.902 | $0.9925 | +0.74% |
| Week 2 | $0.7937 | $0.9087 | $1.04 | +1.49% |
| Week 3 | $0.7756 | $0.9154 | $1.08 | +2.25% |
| Week 4 | $0.7616 | $0.9222 | $1.12 | +3.01% |
| Week 5 | $0.7501 | $0.9291 | $1.15 | +3.77% |
| Week 6 | $0.7404 | $0.936 | $1.18 | +4.54% |
| Week 7 | $0.7321 | $0.9429 | $1.21 | +5.32% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally.
The lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and it completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as being in preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for Parkinson's and CogniC for Alzheimer's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
NeuroSense Therapeutics Ltd. (NRSN) trades at $0.8953, with a market capitalization of $32.32M, and it ranks 4725 by market cap.
The stock shows a 30-day price range from $0.7054 to $1.14, and annualized volatility is 70%. Support is at $0.69 and resistance at $0.95.
The price outlook through the forecast horizon is bullish, with the average price rising across years and a rising return on investment. In 2026 the average price is $0.8953 with an ROI of 0%, and the outlook strengthens in subsequent years with higher averages and positive ROI values through 2050, including a forecast average of $6.85 by 2050.
A major floor 34.7% below — a decisive break under it would weaken the trend.
The nearest floor, 22.9% below — buyers have tended to step in here.
The nearest ceiling, 6.1% above — a clean break opens room to run.
A major ceiling 23.4% above — clearing it would confirm fresh momentum.
Key NRSN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRSN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.834 | Buy | $0.8485 | Buy |
| MA 10 | $0.8213 | Buy | $0.835 | Buy |
| MA 20 | $0.8448 | Buy | $0.8247 | Buy |
| MA 50 | $0.7843 | Buy | $0.819 | Buy |
| MA 100 | $0.8533 | Buy | $0.8649 | Buy |
| MA 200 | $0.976 | Sell | $0.9715 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 59.88 | Neutral |
| Stoch RSI (14) | 96.95 | Sell |
| CCI (20) | 82.28 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | 1.70 | Buy |
| Bollinger %B (20,2) | 0.76 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.25 | Buy |
| Awesome (5,34) | 0.04 | Buy |
| Ultimate (7,14,28) | 58.82 | Neutral |
| Momentum (10) | 0.06 | Buy |
| Aroon Osc (25) | 40.00 | Buy |
| Hull MA (9) | 0.86 | Buy |
| ADX (14) | 14.57 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is bullish, supported by a bullish sentiment reading.
The RSI(14) is 60, with the SMA50 at $0.7843 and the SMA200 at $0.976, framing a positive near-term trend. Traders should note resistance at $0.95 and support at $0.69 as key levels to watch.
The 30-day range spans $0.7054 to $1.14, indicating a relatively wide intraday movement but a bias toward upward movement in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.69 | $0.8953 | $1.20 | 0% | Neutral | |
| $0.7767 | $1.01 | $1.41 | +13% | Neutral | |
| $0.9014 | $1.22 | $1.77 | +36% | Bullish | |
| $1.13 | $1.58 | $2.38 | +76% | Bullish | |
| $1.17 | $1.68 | $2.61 | +87% | Bullish | |
| $1.16 | $1.70 | $2.72 | +90% | Bullish | |
| $1.19 | $1.79 | $2.92 | +100% | Bullish | |
| $1.16 | $1.79 | $2.99 | +100% | Bullish | |
| $1.27 | $2.01 | $3.41 | +124% | Bullish | |
| $1.48 | $2.38 | $4.13 | +166% | Bullish | |
| $1.80 | $3.20 | $5.97 | +257% | Bullish | |
| $3.22 | $6.85 | $14.20 | +665% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.69 | $0.8953 | $1.06 | +0.00% |
| June 2026 | $0.7966 | $0.9422 | $1.15 | +5.23% |
| July 2026 | $0.8244 | $0.986 | $1.22 | +4.65% |
| August 2026 | $0.803 | $0.9689 | $1.22 | -1.73% |
| September 2026 | $0.7974 | $0.9692 | $1.23 | +0.03% |
| October 2026 | $0.8202 | $1.00 | $1.29 | +3.56% |
| November 2026 | $0.7979 | $0.9822 | $1.27 | -2.13% |
| December 2026 | $0.7449 | $0.9222 | $1.20 | -6.11% |
Click any year to see its month-by-month NRSN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NRSN could reach as high as $1.20, with a base case around $0.8953 and support toward $0.69 — roughly 0% from $0.8953. Price action looks broadly range-bound.
Expect NRSN to range from $0.7767 to $1.41 through 2027. The $1.01 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. A consolidation phase looks the most probable path here.
The NRSN price prediction for 2028 points to an average of $1.22 (low $0.9014, high $1.77) — a potential gain of +36% on today's $0.8953. Momentum favours further upside here.
In 2029, NRSN is projected to trade between $1.13 and $2.38, averaging $1.58 — a potential gain of +76% from today's $0.8953. That is up +29% on the projected 2028 average. Buyers look set to stay in control over this stretch.
NeuroSense Therapeutics Ltd.'s 2030 outlook centres on $1.68, within a $1.17 to $2.61 range. That is up +6% on the projected 2029 average. That marks a +87% change versus current levels. Momentum favours further upside here.
By 2031, NRSN could reach as high as $2.72, with a base case around $1.70 and support toward $1.16 — roughly +90% from $0.8953. Buyers look set to stay in control over this stretch.
Expect NRSN to range from $1.19 to $2.92 through 2032. The $1.79 average target implies a +100% move from current prices. That is up +5% on the projected 2031 average. Momentum favours further upside here.
The NRSN price prediction for 2033 points to an average of $1.79 (low $1.16, high $2.99) — a potential gain of +100% on today's $0.8953. Buyers look set to stay in control over this stretch.
In 2034, NRSN is projected to trade between $1.27 and $3.41, averaging $2.01 — a potential gain of +124% from today's $0.8953. That is up +12% on the projected 2033 average. Momentum favours further upside here.
NeuroSense Therapeutics Ltd.'s 2035 outlook centres on $2.38, within a $1.48 to $4.13 range. That is up +19% on the projected 2034 average. That marks a +166% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NRSN could reach as high as $5.97, with a base case around $3.20 and support toward $1.80 — roughly +257% from $0.8953. Momentum favours further upside here.
Expect NRSN to range from $3.22 to $14.20 through 2050. The $6.85 average target implies a +665% move from current prices. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NRSN today (≈ 1,116.944041 NRSN) could be worth
$7,650
+$6,650 (+665%) by 2050 · US Dollar
Based on the average projected NRSN price of $6.85 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRSNwould be worth at today's price.
$1,000 invested in NRSN on May 27, 2025 (≈ 657.894745 NRSN) would be worth
$589.01
-$410.99 (-41.1%) today · 0.59× · US Dollar
Based on a NRSN entry price of $1.52 vs. today's $0.8953.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.81 | $1,105.31 | +10.5% |
| 1 month ago | $0.751 | $1,192.14 | +19.2% |
| 3 months ago | $0.902 | $992.57 | -0.7% |
| 6 months ago | $1.19 | $752.35 | -24.8% |
| 1 year ago | $1.52 | $589.01 | -41.1% |
| All time (4.5y) ago | $4.04 | $221.61 | -77.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRSN forecast.
Our base-case forecast reaches $1.80 around 2034.
Implied market cap at $1.80: $64.98M
Looking further out, the multi-year forecast shows a bullish trajectory. For 2030, the average price is $1.68 with a min of $1.17 and a max of $2.61, and the ROI is 87.2% with a bullish sentiment.
In 2040, the average price is projected at $3.20, with a min of $1.80 and a max of $5.97, and the ROI reaches 257.4%, still within a bullish outlook.
By 2050, the average price is forecast at $6.85, with a min of $3.22 and a max of $14.20, and the ROI is 665%, with a bullish sentiment continuing across the horizon.
These figures reflect estimates of future price levels and returns and are not guaranteed. The actual results may vary due to a range of factors.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.68 with a min of $1.17 and a max of $2.61, and an ROI of 87.2%, with a bullish sentiment.
Forecasts show a bullish sentiment from 2030 onward, with increasing average prices and positive ROIs (e.g., 87.2% in 2030, 257.4% by 2040, and 665% by 2050). Early years include neutral sentiment (e.g., 2026 with an ROI of 0%), suggesting mixed near-term performance and higher potential in the longer term.
Yes. The 2040 forecast max is $5.97, and the 2050 forecast max is $14.20, indicating that reaching or exceeding $5 is within the projected range by 2040.
For 2026, the min is $0.69, the avg is $0.8953, and the max is $1.20, with an ROI of 0% and a neutral sentiment.
Current price is $0.8953, and market capitalization is $32.32M, with a rank of 4725.
NeuroSense Therapeutics Ltd. Community Discussion
0Share your NeuroSense Therapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.